Jumar Bioincubator accelerating biotech innovation through strategic partnership

Image of people sitting in a relaxed meeting space

Accelerating Biotech Innovation through Strategic Partnerships
Jumar Bioincubator stands as Australia’s first and only biotech incubator co-located with a global biotech company, situated within Melbourne’s world-class biomedical precinct.

A Vision Born from Collaboration
Established through a landmark partnership between CSL, WEHI (Walter and Eliza Hall Institute of Medical Research), and the University of Melbourne, with initial investment from Breakthrough Victoria, Jumar is designed to nurture early-stage and scaling biotech ventures, providing them with the resources, expertise, and collaborative environment needed to transform discoveries into real-world treatments and therapies.

The vision for Jumar Bioincubator was born from the shared ambition of CSL, WEHI, and the University of Melbourne to position Melbourne as a globally recognised hub for biotech translation and commercialisation.

“Turning medical research into breakthrough therapies and technologies is a complex and demanding journey. As a proud Australian success story with a global footprint, CSL embraces its responsibility to nurture the next generation of innovators. Through our partnership with WEHI and the University of Melbourne, we are thrilled to provide this support from CSL’s Global Headquarters in Melbourne and help pave the way for more outstanding biotech companies in the years ahead, ” said Dr Michael Wilson, SVP Head of Research, CSL.

Internationally, there is clear evidence that demonstrates the value that incubators can bring to start-up ventures. Cicada Innovations, Jumar’s Operator, reports that startups supported by incubators like Jumar have an 85% five-year survival rate and a 40% faster growth trajectory compared to standalone entities. High quality laboratory space and access to research infrastructure through incubators is equally as important as the collaborative environment that encourages engagement with like-minded peers and companies.

An established and attractive biotech precinct requires numerous components working in synergy: world class research; cutting edge infrastructure and facilities; investment support for innovations across the development lifecycle; the ability to translate the research into commercial outcomes, and above all, collaboration. Jumar is an example of the ‘magic’ that can occur when all of these components come together to create something, that each on its own, can’t do.

Jumar’s Impact
Since its official opening in April 2024, Jumar Bioincubator has welcomed 37 innovative early-stage ventures, working on critical health challenges across pharmac euticals, diagnostics, medical devices, bioinformatics, and health-related AI. Notable resident companies include:

  • Denteric: Developing therapies for periodontal gum disease, a condition affecting one third of adults globally. https://www.denteric.com/
  • Symex Labs: Pioneering a wearable “lab-on-a-chip” for continuous hormone monitoring to aid conception. https://symexlabs.com/
  • Tessara Therapeutics: Creating 3D neural micro-tissues (“mini brains”) to accelerate drug discovery for neurodegenerative diseases. https://www.tessaratherapeutics.com/
  • Rage Bio: developing precision therapeutics using RNA-targeting to fight chronic inflammatory disease including lung diseases such as COPD. https://www.ragebio.com/